Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report suggests that intradermal botulinum toxin type A may alleviate pruritus and reduce papules in Fox-Fordyce disease, improving quality of life without serious adverse effects for at least six months.

In this case report, off-label onabotulinumtoxin-A was successfully used to treat trichodynia, a painful scalp sensation associated with hair loss, in a patient unresponsive to conventional therapies.

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

This study reported improvement in an 11-year-old boy with refractory alopecia areata after 4 months of treatment with oral abrocitinib, a JAK1 inhibitor, suggesting it may be a potential alternative for pediatric patients unresponsive to conventional therapies.

The study suggests that refractory chronic alopecia areata cases have more infiltrating skin resident memory T cells, and using a JAK inhibitor may be an effective treatment option.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

This study found that intramuscular triamcinolone acetonide may be an effective and safe treatment option for managing refractory alopecia areata, showing a 63% response rate in patients and hair regrowth negatively correlated with initial scalp involvement.

This study suggests that scalp rolling could be a promising and affordable adjuvant treatment for alopecia areata, potentially promoting hair regrowth by enhancing the effects of topical medications and inducing collagen.

In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.

In this study, researchers evaluated the use of adipocyte-derived stem cell conditioned media combined with fractional laser or microneedling for treating refractory alopecia areata, finding that 64.3% of patients had significant hair regrowth, suggesting this combination may be an effective and safe treatment option.

This study presents two cases where intralesional methotrexate combined with ablative fractional CO2 laser treatment resulted in excellent outcomes for refractory alopecia areata.

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

This study found that while 51.3% of severe alopecia areata patients achieved significant hair regrowth with intravenous methylprednisolone, oral Janus kinase inhibitors may benefit those who do not respond to this treatment.

A new surgical technique using vellus hair grafts effectively treated vitiligo without causing unwanted hair growth.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

In this study, researchers identified a unique variant of alopecia areata characterized by an increase in telogen hair follicles and minimal inflammation present in the microenvironment.

This review summarizes current treatments for recalcitrant alopecia areata and recent therapeutic developments targeting specific immunological pathways, reporting no new clinical results.

This case report observed marked hair regrowth in a patient with refractory alopecia areata using a combination of platelet-rich plasma, low-level light therapy, and microneedling alongside topical and oral agents.

In this study, seven patients with refractory alopecia areata treated with concentrated growth factor and microneedling-assisted betamethasone experienced significant hair regrowth, with one achieving over 50% regrowth and six showing complete recovery, without adverse effects.

This study found that baricitinib, taken for 24 weeks, significantly reduced alopecia severity in patients with moderate-to-severe alopecia areata, with 50% showing marked improvement and overall favorable safety and efficacy reported.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, primarily pitting, and this was significantly associated with longer disease duration but not disease severity.

In this case study, a 39-year-old Japanese woman with severe alopecia areata demonstrated complete hair regrowth after one year using a combination of 0.5% delgocitinib ointment and excimer laser, suggesting potential efficacy and safety compared to conventional treatments.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

This study found that topical cyclosporin-A may lead to moderate recovery in patients with severe or refractory alopecia areata, particularly in focal type cases.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, and while this was associated with longer disease duration, it did not correlate with the severity of scalp hair loss.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, predominantly pitting, which was significantly linked to longer disease duration but not the severity of scalp hair loss.